Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trends in Lung Cancer Molecular Testing.

The West Virginia medical journal - 1 Jan 2000

Smolkin Matthew B, Almubarak Mohammed, Perrotta Peter L

Abstract excerpt

Molecular testing of non-small cell lung carcinomas (NSCLCC) with adenocarcinoma features has become commonplace with the development and use of targeted treatments for these malignancies. Prior to treating these tumors with targeted drug regimens, testing for specific mutations is usually required to determine the potential response of the tumor to the therapeutic agents. This case review describes a patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Mutation

Source

Identifiers

PMID: 26521535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trends in Lung Cancer Molecular Testing.PMID 26521535Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Molecular Testing in Lung Cancer: Recommendations and Update.Semantic proximity Read ↗

Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression.Semantic proximity Read ↗

Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Present and future molecular testing of lung carcinoma.Semantic proximity Read ↗

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.Semantic proximity Read ↗

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.